Proteomics International (ASX: PIQ) is a precision diagnostics company focused on the development and commercial launch of first-in-class blood-based diagnostic tests targeting diseases that are often detected late and are costly to manage. The Company operates a platform-based model, combining proprietary biomarkers, validated clinical data, accredited laboratories, and a digital sales pathway to support direct sales and future licensing across multiple tests and jurisdictio